Table 2.

Immunorecognition of 14F7 Mab in malignant lesions derived from human skin.

Samples	No. cases (%)	Range intensity	Positive cells
(i) Nonmelanoma skin tumors
Basal cell carcinoma	2/13 (15.4)	+/++	1
Solid	0/7	−	0
Adenoid	2/5 (40)	+/++	1
Keratotic	0/1	−	0
Squamous cell carcinoma	4/8 (50)	+/+++	1/2
Well differentiated	2/6 (33.3)	+++	2
Ulcerated	2/2	+	1
(ii) Cutaneous malignant melanoma	28/28 (100)	+++	3
Melanotic	27/27	+++	3
Amelanotic	1/1	+++	3
(iii) Lymph node metastases	6/7 (85.7)	++/+++	1/3

Intensity: − negative, + weak, ++ moderate, +++ intense. Positive cells: 0 (negative to less than 5%), 1 (6–25%), 2 (26–50%) and 3 (more than 50%).